# EDGAR Filing Document

**Accession Number:** 0001137883
**File Stem:** 0001104659-25-062595
**Filing Date:** 2025-6
**Character Count:** 17092
**Document Hash:** 688c6ec06d1a71f6d85f9380016cefe7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-062595.hdr.sgml**: 20250625

**ACCESSION NUMBER**: 0001104659-25-062595

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250625

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250625

**DATE AS OF CHANGE**: 20250625

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BRAINSTORM CELL THERAPEUTICS INC.
- **CENTRAL INDEX KEY:** 0001137883
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 207273918
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36641
- **FILM NUMBER:** 251074005

**BUSINESS ADDRESS:**
- **STREET 1:** 1325 AVENUE OF AMERICAS
- **STREET 2:** 28TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019
- **BUSINESS PHONE:** 201-488-0460

**MAIL ADDRESS:**
- **STREET 1:** 1325 AVENUE OF AMERICAS
- **STREET 2:** 28TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BRAINSTORM CELL THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20041122

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GOLDEN HAND RESOURCES INC
- **DATE OF NAME CHANGE:** 20030827

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** WIZBANG TECHNOLOGIES INC
- **DATE OF NAME CHANGE:** 20010409

?xml version='1.0' encoding='ASCII'?

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 8-K** 

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** 

Date of Report (Date of earliest event reported): June 25, 2025

**Brainstorm Cell Therapeutics Inc.** 

(Exact name of registrant as specified in its charter)

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Delaware** |  | **001-36641** |  | **20-7273918** |
| *(State or other jurisdiction of <br> incorporation)* | | *(Commission File No.)* | | *(IRS Employer Identification No.)* |

---

---

| | |
|:---|:---|
| **1325 Avenue of Americas, 28th Floor** |  |
| **New York, NY** | **10019** |
| *(Address of principal executive offices)* | *(Zip Code)* |

---

**(201) 488-0460** 

*(Registrant's telephone number, including area code)*

**N/A**

*(Former name or former address, if changed since last report)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| Title of each class | Name of each exchange on which registered |
| Common Stock, $0.00005 par value BCLI | &nbsp;&nbsp; NASDAQ Stock Market LLC<br> (Nasdaq Capital Market) |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 5.02.&nbsp;&nbsp;&nbsp;&nbsp;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

***Amendments to the 2014 Stock Incentive Plan and 2014 Global Share Option Plan***

As described below, on June 25, 2025, Brainstorm Cell Therapeutics Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"), virtually via the internet, and the stockholders of the Company approved Amendment No. 5 to the 2014 Stock Incentive Plan, as amended, and Amendment No. 5 to the 2014 Global Share Option Plan, as amended (collectively, the "Amendments to the 2014 Plans"). The Amendments to the 2014 Plans amend each of the 2014 Stock Incentive Plan, as amended, and 2014 Global Share Option Plan, as amended, respectively (collectively, the "Original 2014 Plans") to increase the shared pool of shares of the Company's common stock, par value $0.00005 per share (the "Common Stock") available for issuance under the Company's Original 2014 Plans by 2,000,000 shares of Common Stock, resulting in a shared pool of 2,906,666 shares of Common Stock.

The Company's officers and directors are among the persons eligible to receive awards under the Original 2014 Plans, as amended by the Amendments to the 2014 Plans, in accordance with the terms and conditions thereunder. A detailed summary of the Original 2014 Plans, as amended by the Amendments to the 2014 Plans, is set forth in Proposal No. 4 in the Company's Definitive Proxy Statement on Schedule 14A for the Annual Meeting, which was filed with the U.S. Securities and Exchange Commission on May 16, 2025 (the "Proxy Statement"). Such detailed summary of the Original 2014 Plans, as amended by the Amendments to the 2014 Plans and the foregoing description of the Original 2014 Plans, as amended by the Amendments to the 2014 Plans, are qualified in their entirety by reference to the full text of the Original 2014 Plans and the Amendments to the 2014 Plans, copies of which are filed as Exhibits 10.1 through 10.12 to this Current Report on Form 8-K and are incorporated by reference herein.

**Item 5.07** **&nbsp;&nbsp;&nbsp;&nbsp;Submission of Matters to a Vote of Security Holders.**

At the Annual Meeting, the Company's stockholders voted on the proposals set forth below, each of which is described in greater detail in the Proxy Statement. The following actions were taken at the Annual Meeting:

1. Stockholders elected the seven (7) nominees (listed below) for election to the Company's Board to hold office until the next annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier resignation or removal, based upon the following votes:

---

| | | | |
|:---|:---|:---|:---|
|  | **Votes For** | **Votes<br> Withheld** | **Broker<br> Non-Votes** |
| Dr. Irit Arbel | 1019207 | 106061 | 2556446 |
| Dr. Menghisteab Bairu | 988227 | 137041 | 2556446 |
| Dr. Jacob Frenkel | 1043878 | 81390 | 2556446 |
| Nir Naor | 958146 | 167122 | 2556446 |
| Dr. Anthony Polverino | 1046623 | 78645 | 2556446 |
| Uri Yablonka | 956788 | 168480 | 2556446 |
| Dr. Stacy Lindborg | 1055967 | 69301 | 2556446 |

---

2. Stockholders approved the proposal to ratify the appointment of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network, as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2025, based upon the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 3346891 | 315162 | 19661 | 0 |

---

3. Stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of the Company's Common Stock, issuable upon the exercise of the Common Warrant in an amount equal to or in excess of twenty percent (20%) of the shares of the Company's Common Stock outstanding immediately prior to the issuance of such warrant, based upon the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 874965 | 236549 | 13754 | 2556446 |

---

4. Stockholders approved amendments to the Company's Original 2014 Plans to increase the shared pool of shares available for issuance under the Original 2014 Plans by 2,000,000 shares from 906,666 shares to 2,906,666 shares based upon the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 758668 | 362809 | 3791 | 2556446 |

---

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

(d): Exhibits:

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Description</u>** |
| [10.1](https://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-1.htm) | [Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan, incorporated by reference to Exhibit 10.1 of Current Report on Form 8-K (File No. 000-54365) filed August 15, 2014.](https://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-1.htm) |
| [10.2](https://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) | [Amendment No. 1 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan, incorporated by reference to Appendix A of the Definitive Proxy Statement on Schedule 14A (File No. 000-36641) filed May 11, 2016.](https://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) |
| [10.3](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-1.htm) | [Amendment No. 2 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan, incorporated by reference to Exhibit 10.1 of Current Report on Form 8-K (File No. 001-36641) filed November 30, 2018.](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-1.htm) |
| [10.4](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) | [Amendment No. 3 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan, incorporated by reference to Appendix A of the Definitive Proxy Statement on Schedule 14A (File No. 001-36641) filed October 1, 2020.](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) |
| [10.5](https://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-1.htm) | [Amendment No. 4 to Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan, incorporated by reference to Exhibit 10.1 of Current Report on Form 8-K (File No. 001-36641) filed September 16, 2024.](https://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-1.htm) |
| [10.6\*](tm2518995d1_ex10-6.htm) | [Amendment No. 5 to Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan.](tm2518995d1_ex10-6.htm) |
| [10.7](https://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-2.htm) | [Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan, incorporated by reference to Exhibit 10.2 of Current Report on Form 8-K (File No. 000-54365) filed August 15, 2014.](https://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-2.htm) |
| [10.8](https://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) | [Amendment No. 1 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan, incorporated by reference to Appendix B of the Definitive Proxy Statement on Schedule 14A (File No. 000-36641) filed May 11, 2016.](https://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) |
| [10.9](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-2.htm) | [Amendment No. 2 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan, incorporated by reference to Exhibit 10.2 of Current Report on Form 8-K (File No. 001-36641) filed November 30, 2018.](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-2.htm) |
| [10.10](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) | [Amendment No. 3 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan, incorporated by reference to Appendix A of the Definitive Proxy Statement on Schedule 14A (File No. 001-36641) filed October 1, 2020.](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) |
| [10.11](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-10.htm) | [Amendment No. 4 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan, incorporated by reference to Exhibit 10.10 of Current Report on Form 8-K (File No. 001-36641) filed September 16, 2024.](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-10.htm) |
| [10.12\*](tm2518995d1_ex10-12.htm) | [Amendment No. 5 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan.](tm2518995d1_ex10-12.htm) |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |

---

**\* Filed herewith.** 

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **BRAINSTORM CELL THERAPEUTICS INC.** | **BRAINSTORM CELL THERAPEUTICS INC.** |
| Date: June 25, 2025 | By: | /s/ Chaim Lebovits |
|  |  | Chaim Lebovits |
|  |  | Chief Executive Officer |

---

## Exhibit 10.6

**Exhibit 10.6**

**BRAINSTORM CELL THERAPEUTICS INC.**

**AMENDMENT NO. 5 TO 2014 STOCK INCENTIVE PLAN**

The 2014 Stock Incentive Plan (the "Plan") of Brainstorm Cell Therapeutics Inc., a Delaware corporation (the "Company"), is hereby amended by this AMENDMENT NO. 5 as follows:

Section 4(a)(1) of the Plan is hereby deleted in its entirety and a new Section 4(a)(1) is inserted in lieu thereof which shall read as follows:

"(1). Authorized Number of Shares. Subject to adjustment under Section 7, Awards may be made under the Plan for up to 2,906,666 shares (which number reflects any stock split or reverse stock split prior to the date of its adoption, and which number shall be automatically adjusted after the date of its adoption in accordance with Section 7(a) below) of common stock, $0.00005 par value per share, of the Company (the "Common Stock"). Subject to such overall limitation, no more than 2,906,666 shares of Common Stock (subject to adjustment under Section 7) may be issued under the Plan in the form of Incentive Stock Options (as defined in Section 5(b)). Shares issued under the Plan may consist in whole or in part of authorized but unissued shares or treasury shares."

Except as set forth above, the remainder of the Plan remains in full force and effect.

\*\*\*\*\*\*\*\*\*\*

Adopted by the Board of Directors of the Company: May 6, 2025.

Adopted by the Stockholders of the Company: June 25, 2025.

## Exhibit 10.12

**Exhibit 10.12**

**BRAINSTORM CELL THERAPEUTICS INC.**

**AMENDMENT NO. 5 TO 2014 GLOBAL SHARE OPTION PLAN**

The 2014 Global Share Option Plan (the "Plan") of Brainstorm Cell Therapeutics Inc., a Delaware corporation (the "Company"), is hereby amended by this AMENDMENT NO. 5 as follows:

Section 5.1 of the Plan is hereby deleted in its entirety and a new Section 5.1 is inserted in lieu thereof which shall read as follows:

"5.1 The Company has reserved 2,906,666 authorized but unissued Shares for the purposes of the Plan and for the purpose of the Company's other share option plans when applicable, subject to adjustment as set forth in Section 7 below. The pool of shares available for issuance under the Plan is the same pool of shares reserved and available for issuance under the 2014 U.S. Stock Option and Incentive Plan (the "U.S. Plan"). Accordingly, shares issued pursuant to awards under either the Plan or the U.S. Plan shall reduce the number of shares available for future issuance under each plan. The shares available for issuance under the U.S. Plan and the Plan may be authorized but unissued shares of Stock or shares of Stock reacquired by the Company. Any Shares which remain unissued and which are not subject to outstanding Awards at the termination of the Plan shall cease to be reserved for the purpose of the Plan, but until termination of the Plan the Company shall at all times reserve a sufficient number of Shares to meet the requirements of the Plan. Should any Award for any reason expire or be canceled prior to its exercise or relinquishment in full, the Share or Shares subject to such Award may again be subjected to an Award under the Plan or under future plans."

Except as set forth above, the remainder of the Plan remains in full force and effect.

\*\*\*\*\*\*\*\*\*\*

Adopted by the Board of Directors of the Company: May 6, 2025.

Adopted by the Stockholders of the Company: June 25, 2025.